Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer

Trastuzumab deruxtecan extended its superiority versus chemotherapy into HER2-ultralow

Related Keywords

United States ,Italy ,Boston ,Massachusetts ,Milan ,Lombardia ,Chicago ,Illinois ,American ,Julie Gralow ,Giuseppe Curigliano ,Charles Bankhead ,Erica Mayer ,American Society Of Clinical Oncology ,European Institute Of Oncology ,University Of Milan ,European Institute ,American Society ,Clinical Oncology ,Dana Farber Cancer ,Medpage Today ,